— peptide —
Long-acting amylin receptor agonist investigated as a monotherapy and in fixed-combination research with semaglutide for body-weight regulation.
From Retail $71 USDT
Member $62.00 USDT
Members save 15% — free to join
Order now to reserve — we'll ship as soon as inventory is replenished.
Research-grade material. Documentation summarizes published literature in third-person scientific context. Not medical advice; not for human consumption.
— Pricing —
All prices in USDT. Crypto pays settle directly to our wallet.
Single vial
Retail $71 USDT
Member $62.00 USDT
Members save 15% — free to join
1 vial · $62.00 USDT per vial
Most flexible
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
5-Pack
Save 14%Retail $307 USDT
Member $267.00 USDT
Members save 15% — free to join
5 vials · $53.40 USDT per vial
Researcher's choice
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
10-Pack
Best valueRetail $446 USDT
Member $388.00 USDT
Members save 15% — free to join
10 vials · $38.80 USDT per vial
Pre-order reserves your spot in the restock queue.
USDT settlement · 3% off if you pay in crypto.
— The literature —
Cagrilintide acts as an agonist at the amylin receptor complexes AMY1, AMY2, and AMY3, which are formed by heterodimerization of the calcitonin receptor with receptor activity-modifying proteins 1, 2, or 3. Receptor activation couples through Gas to adenylyl cyclase, elevating intracellular cAMP. Cagrilintide also retains affinity for the calcitonin receptor itself, distinguishing it from earlier amylin analogs such as pramlintide.
Within the brainstem, amylin receptors in the area postrema and nucleus tractus solitarius mediate observed reductions in food intake and meal size in preclinical feeding studies. The molecule also engages receptors in the hypothalamic arcuate nucleus and lateral parabrachial nucleus, contributing to homeostatic satiety. Peripheral actions include slowed gastric emptying and suppression of postprandial glucagon secretion. The complementary anatomical distribution of amylin and GLP-1 receptors provides a mechanistic rationale for combination studies with semaglutide.
All compounds discussed are intended for research use only. Not for human consumption. Research-context information is educational and does not constitute medical advice.
View the full disclaimer →— Available strengths —